Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)

Status:
Completed

Trial end date:
2006-11-01

Target enrollment:

Participant gender:

This study is designed to compare a range of doses of GW856553 versus placebo on the biomarkers associated with rheumatoid arthritis

Phase 2

GlaxoSmithKline